Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allen S Yang

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Seminars in Hematology|January 13, 2015
Development of romiplostim: a novel engineered peptibodyAllen S Yang
Epigenomics|December 25, 2015
The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitorsAllen S Yang, Brandon J Yang
Cancer Biology & Therapy|July 25, 2003
Mitoxantrone: a hypomethylating agent?Allen S Yang, Jean-Pierre J Issa
Journal of Hematology & Oncology|November 14, 2009
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinibDavid Masiello, Gerry Gorospe, Allen S Yang
Epigenomics|November 30, 2011
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumorsLisa A Cowan, Sundeep Talwar, Allen S Yang
Clinical Advances in Hematology & Oncology : H&O|January 17, 2008
Evaluating new treatment options for MDSGuillermo Garcia-Manero, Allen S Yang, Madan Jagasia
Journal of Biomedical Science|February 4, 2012
Mono-allelic retrotransposon insertion addresses epigenetic transcriptional repression in human genomeHyang-Min Byun, Kyu Heo, Kasey J Mitchell, et al.
Journal of Hematology & Oncology|July 28, 2009
Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective studyJustin P Lee, Elliott Birnstein, David Masiello, et al.
Nucleic Acids Research|September 16, 2010
Identification of preferential target sites for human DNA methyltransferasesSi Ho Choi, Kyu Heo, Hyang-Min Byun, et al.
British Journal of Haematology|August 10, 2007
Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibitionSi Ho Choi, Hyang-Min Byun, Jennifer M Kwan, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Seminars in Hematology|January 13, 2015
Development of romiplostim: a novel engineered peptibodyAllen S Yang
Epigenomics|December 25, 2015
The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitorsAllen S Yang, Brandon J Yang
Cancer Biology & Therapy|July 25, 2003
Mitoxantrone: a hypomethylating agent?Allen S Yang, Jean-Pierre J Issa
Journal of Hematology & Oncology|November 14, 2009
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinibDavid Masiello, Gerry Gorospe, Allen S Yang
Epigenomics|November 30, 2011
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumorsLisa A Cowan, Sundeep Talwar, Allen S Yang
Clinical Advances in Hematology & Oncology : H&O|January 17, 2008
Evaluating new treatment options for MDSGuillermo Garcia-Manero, Allen S Yang, Madan Jagasia
Journal of Biomedical Science|February 4, 2012
Mono-allelic retrotransposon insertion addresses epigenetic transcriptional repression in human genomeHyang-Min Byun, Kyu Heo, Kasey J Mitchell, et al.
Journal of Hematology & Oncology|July 28, 2009
Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective studyJustin P Lee, Elliott Birnstein, David Masiello, et al.
Nucleic Acids Research|September 16, 2010
Identification of preferential target sites for human DNA methyltransferasesSi Ho Choi, Kyu Heo, Hyang-Min Byun, et al.
British Journal of Haematology|August 10, 2007
Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibitionSi Ho Choi, Hyang-Min Byun, Jennifer M Kwan, et al.
Pageof 4